Olainfarm increases profitability and earns 7.5 million euros in nine months
Unaudited consolidated Income Statement of JSC Olainfarm for nine months of 2018 shows that the sales of the Group have reached 89.5 million euros, which is a slight decrease by 1% compared to the same period of 2017. At the same time, the company managed to increase its profitability - in the nine months of this year, JSC Olainfarm has earned 7.5 million euros, which is an increase of 13% over the nine months of 2017.
In nine months of 2018, sales volumes continued to increase in all of its major outlets, with the exception of Russia and Kazakhstan, where sales fell by 7% and 14% accordingly. Projected Russian ruble fluctuations impacted planned decrease in sales volumes in Russia, while the increased presence in both Latvian and Belarusian markets had a positive effect on a significant increase in sales in these markets.
The biggest sales increase during the 9 months of 2018 was achieved in Tajikistan, where sales grew by 64%, and in Belarus, where sales increased by 42%. Considerable sales increase (by 17%) was also achieved in Latvia, which resulted in total sales in Latvia being comparable to those of Russia. In total in top 10 of the markets of the Group during this 9-month period The Netherlands and Turkmenistan were replaced by Poland and Tajikistan. Major sales markets of Olainfarm in 9 months of 2018 were Russia, Latvia, Belarus and Ukraine. In reporting period, the Company was selling its products to 50 markets worldwide.
Although the sales in nine months of 2018 slightly lagged behind last year achievement, the Company managed to increase its earnings by more than 850 thousand euros. Major positive factor was that write offs of long-term assets during these nine months were smaller by more than 1.6 million euros, while the major negative change was an increase of COGS by one million euros.
While analyzing the activities of the Olainfarm Group in the 3rd quarter, it should be noted that this 3rd quarter in terms of profit is the most successful third quarter for the Company since 2015. Even despite foreign exchange loss increasing by almost 200 thousand euros, the net profit of third quarter reached 1.7 million euros, which represents an increase of 86% compared to the third quarter of 2017. Major factors influencing the profit increase were write offs of long-term investments being by 700 thousand smaller and write offs of other assets being by 400 thousand smaller than one year ago.
During the 3rd quarter of 2018, compared to the 3rd quarter of 2017, sales of the Company shrunk by less than 0.02% and reached 27.661 million euros, making this third quarter still one of the most successful in terms of sales in corporate history. Despite reduced sales to WHO program, the company has actually managed to repeat the sales volume of last year’s third quarter.
Compared to 9 months period of 2017, this year some significant changes have occurred to the sales structure of bestselling products of Olainfarm. Remantadine and PASA are replaced by Meldonium and Memantine, Share of Noofen, soluble Furaginum and Etacizin have significantly increased, while share of Adaptol in sales of Olainfarm products has experienced some considerable reduction.
Annual meeting of shareholders of JSC Olainfarm, convened on June 5, 2018 approved operating plan of the Group for 2018. According to it, sales of the Group in 2018 are planned to be 130 million euros, but the net profit will reach 11.5 million euros. According to this unaudited report for nine months of 2018, during this period 69% of annual sales target and 65% of annual profit target is met. Management of the Company does not expect the actual revenues and earnings of the company to show any significant deviations from approved. guidance.
| Condensed Consolidated Statement of Financial Position |
|EUR '000||EUR '000|
|Intangible assets||36 734||37 034|
|Property, plant and equipment||42 844||41 892|
|Investment properties||3 501||3 526|
|Financial assets||1 066||2 609|
|TOTAL NON-CURRENT ASSETS||84 145||85 061|
|Inventories||26 358||24 161|
|Receivables||32 267||34 049|
|Cash||4 002||3 158|
|TOTAL CURRENT ASSETS||62 627||61 368|
|TOTAL ASSETS||146 772||146 429|
EQUITY AND LIABILITIES
|Share capital||19 719||19 719|
|Share premium||2 504||2 504|
|Other components of equity||(157)||(74)|
|Retained earnings||79 802||75 675|
|TOTAL EQUITY||101 868||97 824|
|Borrowings||9 523||15 878|
|Deferred income||2 827||2 347|
|Total Non-Current Liabilities||12 350||18 225|
|Borrowings||15 974||14 013|
|Trade payables and other liabilities||14 608||15 892|
|Dividends payable||1 549||-|
|Total Current Liabilities||32 554||30 380|
|TOTAL LIABILITIES||44 904||48 605|
|TOTAL EQUITY AND LIABILITIES||146 772||146 429|
| Consolidated statement of comprehensive income ||Group||Group|
|Q3 2018||Q3 2017||M9 2018||M9 2017|
|EUR '000||EUR '000||EUR '000||EUR '000|
|Net revenue||27 661||27 665||89 505||90 384|
|Cost of goods sold||(10 909)||(10 921)||(35 804)||(34 851)|
|Gross Profit||16 752||16 744||53 701||55 533|
|Selling expense||(8 534)||(8 377)||(26 715)||(27 008)|
|Administrative expense||(5 684)||(5 423)||(17 115)||(16 872)|
|Other operating income||542||732||1 947||1 753|
|Other operating expense||(656)||(1 862)||(2 460)||(3 460)|
|Share of profit of an associate||8||10||83||70|
|Financial expense||(703)||(564)||(1 794)||(1 904)|
|Profit Before Tax||1 743||1 310||7 704||8 318|
|Corporate income tax||(73)||(398)||(250)||(1 806)|
|Deferred corporate income tax||(2)||(17)||-||86|
|PROFIT FOR THE REPORTING PERIOD||1 668||895||7 454||6 598|
|Other comprehensive income for the reporting period||(119)||-||(83)||-|
|Total comprehensive income for the reporting period||1 549||895||7 371||6 598|
|Total comprehensive income attributable to:|
|The equity holders of the Parent Company||1 549||896||7 371||6 597|
|Basic and diluted earnings per share, EUR||0.12||0.06||0.53||0.47|
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top - quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Unaudited consolidated 9 months Income Statement attached.
Information prepared by:
Member of the Management Board
Phone +371 28698449
Upcoming Life Sciences Events
- September 2019
- Boston: 9th Annual American Drug Delivery & Formulation Summit
- Malmo: NLS Days 2019
- Boston: Redefining Early Stage Investments (RESI)